Key Highlights

  • Net loss for the third quarter narrowed to USD 1.67 million, or USD 0.24 per share, from USD 7.80 million, or USD 2.59 per share, a year earlier.
  • A USD 3.3 million non-cash gain on Fair Value adjustments to financial instruments swung other income to USD 3.1 million, against other expense of USD 2.2 million in the prior-year quarter.
  • Operating loss was USD 4.75 million, down 15% from USD 5.62 million, as Research and Development spending fell 40% to USD 2.3 million while general and administrative costs rose 38%.
  • Cash, cash equivalents and short-term investments stood at USD 13.8 million on September 30, 2026, which the company says funds operations into the second half of 2027.

Smaller Loss Driven by a Fair Value Gain, Not Operations

CalciMedica (NASDAQ:CALC) filed its Quarterly Report on November 10, 2026 for the three months ended September 30, 2026. The clinical-stage biopharmaceutical company develops drugs that block calcium release-activated calcium channels, a pathway tied to inflammation and tissue injury. Its net loss was USD 1,674 thousand versus USD 7,804 thousand, a decline of about 79% per the filing. However, the improvement came largely from other income of USD 3,077 thousand, which included a USD 3.3 million gain from fair value adjustments, against a USD 2.0 million loss a year earlier. Loss from operations of USD 4,751 thousand was the cleaner read, and it fell 15%. The company has no approved products and reports no product revenue.

Auxora Pivots to a Phase 2b Plan After FDA Feedback

Research and development expense fell to USD 2.3 million, mainly because nonclinical and clinical-trial costs dropped by USD 1.4 million after enrollment in the KOURAGE kidney injury study was paused in January 2026. The company said an independent committee flagged a mortality imbalance but found no evidence of drug-related toxicity, and the FDA later issued no clinical hold. Following a July 2026 meeting, the FDA aligned on new-onset severe respiratory failure as the primary endpoint for a planned Phase 2b trial of Auxora in acute pancreatitis. The company also plans a Phase 1b pulmonary hypertension study and expects to submit an investigational new drug application for oral candidate CM5480 in mid-2027. General and administrative expense rose to USD 2.4 million on higher professional services.

Going Concern Doubt Persists Despite USD 13.8 Million in Cash

The filing states that its cash may not cover operations for a year and raises substantial doubt about the company continuing as a going concern. The USD 13.8 million is expected to last into the second half of 2027, but it would not be enough to start the Phase 2b trial or fund any candidate through approval. Nine-month net loss was USD 4.35 million, or USD 0.96 per share. Financing since June includes a USD 15.0 million private placement, a 1-for-5 reverse split effective August 28, 2026 and a USD 25.0 million at-the-market Facility filed September 30, 2026. With a small share count, a limited number of trades can move the price, spreads can be wide and quoted moves can reverse.

Where Things Stand

Partly. CalciMedica (NASDAQ:CALC) did report a much smaller loss of USD 1.67 million, but roughly USD 3.3 million of that came from non-cash fair value changes, and the USD 4.75 million operating loss is the steadier figure. Cuts to trial spending helped, yet they reflect the paused kidney study rather than new progress. Auxora has an FDA-aligned endpoint for a planned Phase 2b trial, though the company says it still needs substantial additional capital. Next markers are financing activity, any at-the-market sales, the pulmonary hypertension readout and the CM5480 filing planned for mid-2027.